[Finished Printing? - Click Here to Return to Normal View]


NIDA Home > Funding > Guidelines for Establishing and Operating a Data and Safety Monitoring Board    

Guidelines for Establishing and Operating a Data and Safety Monitoring Board - Appendix 1



Initial Protocol Review

Outline of protocol items to be reviewed

Statement of protocol design (e.g., blinding, control group)

Characteristics of study data collection site(s)

Inclusion/exclusion criteria

Randomization/stratification plan

Definition of participants (e.g., screened, enrolled, randomized, training, treated, drop out, lost to follow-up)

Intervention definition

  • Dosage and frequency
  • Manual (specification for behavioral studies)

Reasons to discontinue participation

  • Safety rules
  • Behavioral rules
  • Missed assessments rules

Reasons to change treatment regimen

Outcome measures

  • Primary
  • Secondary

Sample size

  • Calculation
  • Definition of subjects used for calculation (usually those randomized)

Key adherence variables

Key safety variables (e.g., BP, pulse, liver function tests)

Data analysis plan

Interim analysis plan


drugabuse.gov graphic



NIDA Home | Site Map | Search | FAQs | Accessibility | Privacy | FOIA (NIH) | Employment | Print Version


National Institutes of Health logo_Department of Health and Human Services Logo The National Institute on Drug Abuse (NIDA) is part of the National Institutes of Health (NIH) , a component of the U.S. Department of Health and Human Services. Questions? See our Contact Information. Last updated on Friday, May 19, 2006. The U.S. government's official web portal